首页> 外文期刊>Orthopaedic Journal of Sports Medicine >DECREASE PRESCRIBING OF POSTOPERATIVE OPIOIDS IN PEDIATRIC ACL RECONSTRUCTION- TREATMENT TRENDS AT A SINGLE CENTER
【24h】

DECREASE PRESCRIBING OF POSTOPERATIVE OPIOIDS IN PEDIATRIC ACL RECONSTRUCTION- TREATMENT TRENDS AT A SINGLE CENTER

机译:减少单个中心小儿ACL重建治疗趋势的术后阿片类药物

获取原文
       

摘要

Background: Pain control following ACL Reconstruction (ACLR) presents a unique challenge due to age and early rehabilitation needs. Significant efforts have been made to reduce unnecessary opioid prescribing in this vulnerable population, but few have sought to define current practices. Purpose: The purpose of this study is to describe trends in postoperative pain management and assess factors that may mitigate overutilization of opioid medications. Methods: This is a retrospective review of a series of pediatric patients (&18yo) undergoing primary ACLR within an urban academic hospital system over a 5-year period (2014-2018). The period included the gradual introduction of preoperative consenting for opioid use in minors as mandated by state law in 2016. Patient demographics, surgical details, presence of opioid consent, prescribed postoperative medications, prescriber, and indicators of inadequate pain control were collected. Trends in medication prescribing were assessed. Univariate and multivariate analyses were performed to identify factors associated with reduced postoperative opioid prescribing. Results: This study included 687 patients with a mean age of 15.1±1.9 years. The majority underwent ACL reconstruction using hamstring autograft (92.0%) at our main hospital (54.9%). Postoperatively, discharge medication prescribing was performed most frequently (38.1%) by advanced practitioners (NP/PA). While there was no change in the proportion of patients prescribed opioids (&95% of patients) over the 5 year period, the mean number of doses dispensed decreased annually ( Fig. 1 ). This was accompanied by an increase in the annual percentage of patients prescribed oral NSAIDs and acetaminophen during that period. Preoperative opioid consent was obtained in 31.9% of the cohort and these patients received significantly fewer doses of prescribed opioids (25.0 vs. 34.6 doses, p&0.001), while still having a lower rate of uncontrolled pain prompting early unplanned contact via telephone, ED or clinic. Preoperative consenting (IRR 0.764, CI 0.634-0.920, p=0.005) and satellite surgical location (IRR 0.712, CI 0.517-0.979, p=0.037) were identified as significant predictors of decreased number of postoperative opioid doses prescribed following multivariate regression analysis ( Table 2 ). Conclusion: Total doses of postoperative opioids prescribed for pain management in pediatric ACLR have declined in recent years, which appears related to preoperative counseling through mandated opioid consenting and paralleled by greater utilization of non-opioid medications. Continued efforts should be made to identify measures to limit overreliance on these medications and to mitigate issues related to misuse, overdose and addiction.
机译:背景:疼痛控制下前交叉韧带重建(ACLR)提出,由于年龄和早期恢复需求的独特的挑战。显著已经做出努力,以减少这一脆弱人群不必要的阿片类药物的处方,但很少有力图确定目前的做法。目的:本研究的目的是描述术后疼痛管理的发展趋势,并评估可能减少阿片类药物的过度使用的因素。方法:这是一系列儿童患者的回顾性研究在5年期间(2014-2018年)的城市教学医院系统内进行初级ACLR(安培; 18yo; LT)。期间包括逐步引入术前同意对使用阿片类药物在未成年人作为国家法律在2016年病人的人口统计授权,手术细节,阿片同意,处方药,术后,处方和疼痛控制不当的指标存在收集。在用药处方趋势进行了评估。单变量和多变量分析以鉴定具有降低的术后阿片类药物的处方相关的因素。结果:本研究共纳入687例患者15.1±1.9岁,平均年龄。大多数在我们的主要医院(54.9%),使用自体腘绳肌(92.0%)接受了韧带重建。术后,被先进的从业者(NP / PA)进行出院带药处方最常见(38.1%)。虽然有在患者处方阿片类药物的比例没有变化(安培; GT; 95%的患者)比5年期间,分配的剂量的平均数每年减少(图1)。这是伴随着增加的这段期间遵医嘱口服NSAIDs和对乙酰氨基酚的患者年度百分比。在该队列的31.9%,得到的术前阿片同意和这些患者接受显著较少剂量的规定的阿片样物质(25.0对34.6剂量,P&安培; LT; 0.001),同时仍具有不受控制的疼痛的较低速率促使经由电话早无计划接触,ED或诊所。术前同意(IRR 0.764,CI 0.634-0.920,P = 0.005)和卫星外科位置(IRR 0.712,CI 0.517-0.979,P = 0.037)被确定为以下多变量回归分析数规定术后阿片类药物的剂量降低的显著预测(表2)。结论:总剂量规定用于儿科ACLR疼痛,术后阿片类药物近年来有所下降,通过授权阿片同意并通过非阿片类药物更有效地利用平行其似乎与术前咨询。应继续努力以鉴定措施,对这些药物的限制过度依赖,并减轻与滥用,过量和成瘾问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号